Robert Hofmeister Form 3 TCR2 THERAPEUTICS / Robert Hofmeister ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Hofmeister Robert

(Last) (First) (Middle)

TCR2 THERAPEUTICS INC.

100 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/13/2019

3. Issuer Name and Ticker or Trading Symbol
TCR2 THERAPEUTICS INC. [ TCRR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	24,137(1)	D
Common Stock	14,713	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	12/12/2026	Common Stock	35,732	0.74	D
Stock Option (Right to Buy)	(3)	12/06/2027	Common Stock	42,346	0.74	D
Stock Option (Right to Buy)	(4)	07/25/2028	Common Stock	90,720	5.88	D

Explanation of Responses:

1. The shares are subject to a Stock Restriction Agreement dated October 1, 2015. 25% of the shares vested on the first anniversary of the vesting start date of October 1, 2016, with the remainder vesting in 12 equal quarterly installments thereafter.

2. The Reporting Person was granted an option to purchase 50,445 shares on December 13, 2016. 14,713 of such options were previously exercised. 25% of this option vested and became exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

3. 25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

4. 25% of this option shall vest and become exercisable on July 26, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Robert Hofmeister	02/13/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.